Your browser doesn't support javascript.
loading
Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies.
Fathi, Amir T; Kim, Haesook T; Soiffer, Robert J; Levis, Mark J; Li, Shuli; Kim, Annette S; Mims, Alice S; DeFilipp, Zachariah; El-Jawahri, Areej; McAfee, Steven L; Brunner, Andrew M; Narayan, Rupa; Knight, Laura W; Kelley, Devon; Bottoms, Aj S; Perry, Lindsey H; Wahl, Jonathan L; Brock, Jennifer; Breton, Elayne; Ho, Vincent T; Chen, Yi-Bin.
Affiliation
  • Fathi AT; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
  • Kim HT; Department of Data Science, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA.
  • Soiffer RJ; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Levis MJ; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD.
  • Li S; Department of Data Science, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA.
  • Kim AS; Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
  • Mims AS; The Ohio State University Comprehensive Cancer Center, Columbus, OH.
  • DeFilipp Z; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
  • El-Jawahri A; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
  • McAfee SL; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
  • Brunner AM; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
  • Narayan R; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
  • Knight LW; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
  • Kelley D; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
  • Bottoms AS; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
  • Perry LH; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
  • Wahl JL; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Brock J; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Breton E; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD.
  • Ho VT; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Chen YB; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
Blood Adv ; 6(22): 5857-5865, 2022 11 22.
Article in En | MEDLINE | ID: mdl-36150050
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Hematopoietic Stem Cell Transplantation / COVID-19 / Graft vs Host Disease / Myeloproliferative Disorders Type of study: Clinical_trials Limits: Humans Language: En Journal: Blood Adv Year: 2022 Document type: Article Affiliation country: Morocco Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Hematopoietic Stem Cell Transplantation / COVID-19 / Graft vs Host Disease / Myeloproliferative Disorders Type of study: Clinical_trials Limits: Humans Language: En Journal: Blood Adv Year: 2022 Document type: Article Affiliation country: Morocco Country of publication: United States